EL7.AI
StocksMediumUpdated•Originally published 26 February 2026•Updated 26 February 2026•
1 min read

United Therapeutics Beats Q4 Estimates as Analysts Raise Price Targets on Strong Outlook

Key Facts

1United Therapeutics' revenues grew by over 10% in Q4 and FY2025.
2Net income per share increased by approximately 14%, driving a stock rally of over 75%.
3Tyvaso remains the dominant franchise in the Pulmonary Arterial Hypertension (PAH) market.
4Upcoming catalysts include Phase 3 data for ralinepag and TETON-1/2 trials for Idiopathic Pulmonary Fibrosis (IPF).

United Therapeutics Corporation (UTHR) confirmed that its fourth-quarter earnings surpassed Wall Street expectations, with revenues climbing by more than 10%. The company's net income per share saw an impressive increase of approximately 14%, fueling a significant stock rally of over 75% as investor confidence surged. Following this strong performance, analysts have raised their future forecasts and price targets for the stock, reflecting significant optimism regarding the company's financial trajectory. A primary driver of this success remains the Tyvaso franchise, which continues to dominate the Pulmonary Arterial Hypertension (PAH) market. Looking ahead, the company is positioned for further growth with high-impact clinical catalysts, including Phase 3 data for ralinepag and results from the TETON-1/2 trials. This combination of superior earnings and a promising late-stage clinical pipeline reinforces the company's leadership position in the biotechnology sector.